Explore the latest setbacks for Pfizer's sickle cell disease portfolio as its investigational P-selectin inhibitor, inclacumab, fails to meet its primary endpoint

Lantern Pharma has successfully completed targeted patient enrollment in Japan ahead of schedule for its multi-centre Phase II HARMONIC clinical trial of LP-300. This trial evaluates the safety and efficacy of LP-300, a disulfide small molecule, alongside standard-of-care chemotherapy for never-smoker NSCLC patients who have relapsed after TKI treatment

Clinical trials, the essential process by which new medical treatments are tested and brought to patients, are currently facing a profound crisis. Industry leaders are sounding the alarm, stating that the existing models are simply not sustainable and that without urgent, transformative change,

In the dynamic world of medical research, breakthroughs often emerge from a deep understanding of the body's intricate systems and a dedication to addressing persistent health challenges. One such exciting development comes from Windward Bio

Delve into the complexities of Myasthenia Gravis (MG), a heterogeneous neuromuscular disorder, and explore the evolution of standardized clinical scales and questionnaires used as outcome measures in clinical trials. Understand the shift from objective assessments to patient-reported outcomes (PROs), including key scales like QMG, MG-ADL, MGC, and QOL15(r)

The future of Alzheimer's disease research is brighter than ever! Discover how groundbreaking strategies, including innovative blood-based biomarker tests, virtual clinical trials, and culturally-informed community engagement, are dramatically increasing diverse participation and accelerating the development of urgently needed AD therapies

Alzheimer's disease (AD) is a devastating condition that relentlessly strips away memories, independence, and the very essence of an individual. It impacts millions globally, and the urgent need for effective new therapies cannot be overstated.

Discover how Walgreens is redefining clinical research, transforming patient engagement and recruitment for sponsors. Leveraging advanced AI models and predictive modeling technologies, we identify and match eligible patients to trials, often exceeding recruitment timelines

Breaking News: Get the full, transparent details on why Viatris's investigational MR-139 (pimecrolimus 0.3%) ophthalmic ointment for blepharitis failed its Phase III trial. Discover how the therapy did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing.

Tired of clinical trials sinking $800 million to $1.4 billion and taking 10-15 years to bring a single new drug to market, with high failure rates contributing significantly to inefficiency? Discover how Artificial Intelligence (AI) is revolutionizing drug development, tackling main causes of failure like suboptimal patient selection, recruiting, and monitoring

Embark on Intermountain Healthcare's inspiring journey towards health equity! Discover how they're uniting the power of data with a commitment to culture change to create a fairer healthcare experience for all. From using clever dashboards to uncover disparities to fostering brave conversations about systemic racism, see how Intermountain is taking essential first steps, learning along the way, to build a future where everyone can live their healthiest life. It's a testament to progress, one thoughtful step at a time!

Dementia, a broad term for a decline in mental ability severe enough to interfere with daily life, is a growing global health concern. As populations age, understanding the true scope of dementia becomes crucial for healthcare planning

Discover the extensive applications of Artificial Intelligence (AI) in pharmaceutical and healthcare research. Learn how AI is used for drug discovery, disease diagnosis, including cancer and dementia, and personalized treatment. Explore AI's crucial role in clinical trials, aiding in design, patient selection, monitoring, and analysis, and its potential to uncover valuable insights hidden in clinical protocols. Find out how AI assists in forecasting epidemics and pandemics.

Learn how novel approaches to clinical trial design, including integrated models and adaptive methods, are addressing the high costs and inefficiency of traditional drug development, particularly in Phase II and III trials, to reduce attrition rates and increase productivity.

This research looks at how memory and thinking skills change in middle-aged Spanish people who don't have the brain changes usually seen in Alzheimer's disease. Scientists checked their brain fluid to confirm this. They used special methods to track these changes over time and created new ways to compare their scores that are more sensitive than regular tests. The results suggest these new methods might be slightly better at finding very early, subtle declines in memory, which could be a sign of preclinical Alzheimer's. This study hopes to provide doctors with another tool to help spot early changes that might lead to Alzheimer's later in life.

Acquire knowledge concerning Alzheimer's disease diagnosis, prevailing symptomatic treatments, and ongoing research initiatives dedicated to early intervention strategies and therapeutic approaches targeting amyloid and tau proteins.

Explore the critical topic of minority engagement in US clinical research on the Glassbury Cares Podcast. We discuss the persistent challenges of lower participation rates among racial and ethnic minorities in clinical trials, including HIV research. Understand how distrust of the medical community and research, significantly influenced by historical events like the Tuskegee study, acts as a barrier. Learn about other impediments, such as accessibility issues, time commitments, language barriers, stigma, and limited knowledge. Discover facilitators that encourage participation, including altruism, perceived personal and community benefits, trust, culturally relevant services, and monetary compensation. We examine ethical considerations, the importance of justice, and strategies like community-based participatory research to build trust and address structural barriers